New S1P Receptor Modulators

Experimental Medications: Other Therapeutic Strategies

Previous: Vatelizumab | Next: RPC1063

Data have been presented on several investigational oral agents now in ongoing clinical trials that have a mechanism similar to that of Gilenya (fingolimod). These agents have been well tolerated and reduced lesions related to RRMS. It is hoped that these agents, RPC1063, siponimod (BAF312), ponesimod, and ONO-4641, will maintain or improve on the efficacy and safety of Gilenya. However, researchers continue to remain vigilant with regard to cardiovascular side effects, such as bradycardia (slowed heart rate).

Previous: Vatelizumab | Next: RPC1063